Aptus Pharma Ltd to seek shareholder nod for Rs 44.88 Cr preferential issue at 16th AGM

Aptus Pharma Ltd will hold its 16th Annual General Meeting (AGM) on September 14, 2026. Shareholders will vote on a preferential allotment of 16,02,870 equity shares to raise Rs 44.88 crore.

Reader Takeaway: Capacity expansion plans funded by new capital offer growth potential, but existing shareholder dilution is a consideration.

What just happened

Aptus Pharma Ltd has announced its 16th Annual General Meeting (AGM) scheduled for September 14, 2026. A key agenda item is the proposed preferential allotment of 16,02,870 equity shares at an issue price of Rs 280 per share (face value Rs 10, premium Rs 270). This aims to raise Rs 44.88 crore.

The meeting will be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The cut-off date for determining voting eligibility is September 7, 2026, with e-voting open from September 11 to September 13, 2026.

Why this matters

This preferential issue represents a significant capital infusion for Aptus Pharma. The funds are earmarked for critical growth initiatives, primarily capital expenditure for land acquisition, manufacturing plant construction, and high-tech storage facilities. This expansion is crucial for the company's future production capacity and operational efficiency.

While the issue is not expected to change control of the company, existing shareholders will experience dilution. The outcome of the AGM vote is therefore important for them.

The backstory

This AGM and preferential issue are part of Aptus Pharma's ongoing strategy to fund expansion and strengthen its operational base. The company is looking to enhance its infrastructure to support future growth in manufacturing and logistics.

What changes now

If approved by shareholders, the Rs 44.88 crore raised will be strategically deployed. Rs 25 crore is allocated to capital expenditure over the next 36 months, Rs 10 crore for working capital, and Rs 9.88 crore for general corporate purposes. This will enable the company to move forward with its planned infrastructure development.

Additionally, Mr. Chetan Shantilal Lalseta is retiring by rotation and seeking re-appointment as a Non-Executive Director. His continued presence may provide stability to the board.

Risks to watch

Key risks include potential delays in the execution of capital expenditure projects, overruns in project costs, and the impact of dilution on existing shareholders' earnings per share. The effective utilization of funds for the stated purposes will be crucial.

Peer comparison

While specific peer data isn't in the filing, pharmaceutical companies often raise capital for expanding manufacturing capabilities and R&D. The issue price of Rs 280 per share will be benchmarked against market prices around August 14, 2026, to ensure fair valuation, but actual comparisons would require recent trading data and valuations of similar-sized pharma companies.

Context metrics (time-bound)

• AGM Date: September 14, 2026
• E-voting Period: September 11, 2026 (9 am) to September 13, 2026 (5 pm)
• Preferential Issue Size: Rs 44.88 Crore
• Shares to be Issued: 16,02,870 equity shares
• Issue Price: Rs 280 per share
• Capital Expenditure Allocation: Rs 25 crore (within 36 months)
• Working Capital Allocation: Rs 10 crore
• General Corporate Purposes Allocation: Rs 9.88 crore

What to track next

Investors should track the outcome of the AGM, specifically the shareholder approval for the preferential issue. Post-approval, monitoring the progress of land acquisition, plant construction, and the deployment of funds will be key indicators of the company's growth trajectory.